{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:15:25Z","timestamp":1782306925511,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2017R1A5A2014768"],"award-info":[{"award-number":["NRF-2017R1A5A2014768"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A2C2009281"],"award-info":[{"award-number":["NRF-2022R1A2C2009281"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2019R1A2C1006752"],"award-info":[{"award-number":["NRF-2019R1A2C1006752"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["21153MFDS601"],"award-info":[{"award-number":["21153MFDS601"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neurodegenerative diseases, including Parkinson's disease, Amyotropic Lateral Sclerosis (ALS) and Alzheimer's disease, present significant challenges for therapeutic development due to drug delivery restrictions and toxicity concerns. Prevailing strategies often employ adeno-associated viral (AAV) vectors to deliver neuroprotective survival genes directly into the central nervous system (CNS). However, these methods have been limited by triggering immunogenic responses and risk of tumorigenicity, resulting from overexpression of survival genes in peripheral blood mononuclear cells (PBMC), thereby increasing the risk of tumorigenicity in specific immune cells. Thus, by coding selectively suppressive microRNA (miRNA) target sequences in AAV genome, we designed CNS-targeted neuroprotective gene expression vector system without leakage to blood cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To minimize the potential for transgene contamination in the blood, we designed a CNS-specific AAV system. Our system utilized a self-complementary AAV (scAAV), encoding a quadruple repeated target sequence of the hematopoietic cell-specific miR142-3p at the 3' untranslated region (UTR). As a representative therapeutic survival gene for Parkinson\u2019s disease treatment, we integrated DX2, an antagonistic splice variant of the apoptotic gene AIMP2, known to be implicated in Parkinson's disease, into the vector.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This configuration ensured that transgene expression was stringently localized to the CNS, even if the vector found its way into the blood cells. A single injection of scAAV-DX2 demonstrated marked improvement in behavior and motor activity in animal models of Parkinson\u2019s disease induced by either Rotenone or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Importantly, comprehensive preclinical data adhering to Good Laboratory Practice (GLP) standards revealed no adverse effects in the treated animals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our CNS-specific vector system, which encodes a survival transgene DX2, signifies a promising avenue for safe gene therapy, avoiding unintended expression of survival gene in blood cells, applicable to various neurodegenerative diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04816-x","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T06:02:07Z","timestamp":1705125727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson\u2019s disease treatment"],"prefix":"10.1186","volume":"22","author":[{"given":"Min Hak","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukyeong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Hwan","family":"Um","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyorin","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunghwa","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1177-598X","authenticated-orcid":false,"given":"Jin Woo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"issue":"3","key":"4816_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1517\/17425240902758188","volume":"6","author":"TM Barchet","year":"2009","unstructured":"Barchet TM, Amiji MM. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv. 2009;6(3):211\u201325.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"4816_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1582-4934.2001.tb00134.x","volume":"5","author":"KA Jellinger","year":"2001","unstructured":"Jellinger KA. Cell death mechanisms in neurodegeneration. J Cell Mol Med. 2001;5(1):1\u201317.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"4816_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrg2988","volume":"12","author":"F Mingozzi","year":"2011","unstructured":"Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12(5):341\u201355.","journal-title":"Nat Rev Genet"},{"issue":"6","key":"4816_CR4","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","volume":"19","author":"SJ Gray","year":"2011","unstructured":"Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther. 2011;19(6):1058\u201369.","journal-title":"Mol Ther"},{"issue":"9579","key":"4816_CR5","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet. 2007;369(9579):2097\u2013105.","journal-title":"Lancet"},{"issue":"6","key":"4816_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1089\/hum.2013.238","volume":"25","author":"M Tardieu","year":"2014","unstructured":"Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C, Vincent F, Hocquemiller M, Broissand C, Furlan V, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial. Hum Gene Ther. 2014;25(6):506\u201316.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"4816_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","volume":"7","author":"WJ Marks Jr","year":"2008","unstructured":"Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial. Lancet Neurol. 2008;7(5):400\u20138.","journal-title":"Lancet Neurol"},{"issue":"12","key":"4816_CR8","first-page":"1589","volume":"12","author":"MJ During","year":"2001","unstructured":"During MJ, Kaplitt MG, Stern MB, Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther. 2001;12(12):1589\u201391.","journal-title":"Hum Gene Ther"},{"issue":"20","key":"4816_CR9","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","volume":"73","author":"CW Christine","year":"2009","unstructured":"Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009;73(20):1662\u20139.","journal-title":"Neurology"},{"issue":"1","key":"4816_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bbrc.2018.11.112","volume":"508","author":"H Ji","year":"2019","unstructured":"Ji H, Huang C, Wu S, Kasim V. XBP1-s promotes colorectal cancer cell proliferation by inhibiting TAp73 transcriptional activity. Biochem Biophys Res Commun. 2019;508(1):203\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"4816_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3892\/or.2013.2932","volume":"31","author":"I Kunter","year":"2014","unstructured":"Kunter I, Erdal E, Nart D, Yilmaz F, Karademir S, Sagol O, Atabey N. Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma. Oncol Rep. 2014;31(2):573\u201380.","journal-title":"Oncol Rep"},{"issue":"5","key":"4816_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1358\/dnp.2009.22.5.1378631","volume":"22","author":"AN Shajahan","year":"2009","unstructured":"Shajahan AN, Riggins RB, Clarke R. The role of X-box binding protein-1 in tumorigenicity. Drug News Perspect. 2009;22(5):241\u20136.","journal-title":"Drug News Perspect"},{"issue":"20","key":"4816_CR13","doi-asserted-by":"publisher","first-page":"10983","DOI":"10.1073\/pnas.211430998","volume":"98","author":"JR Testa","year":"2001","unstructured":"Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA. 2001;98(20):10983\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4816_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrn1007","volume":"4","author":"C Soto","year":"2003","unstructured":"Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4(1):49\u201360.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"4816_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.bbrc.2012.03.033","volume":"420","author":"A Zuleta","year":"2012","unstructured":"Zuleta A, Vidal RL, Armentano D, Parsons G, Hetz C. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington\u2019s disease. Biochem Biophys Res Commun. 2012;420(3):558\u201363.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5785","key":"4816_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1126\/science.1129462","volume":"313","author":"AA Cooper","year":"2006","unstructured":"Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson\u2019s models. Science. 2006;313(5785):324\u20138.","journal-title":"Science"},{"issue":"5644","key":"4816_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415\u20139.","journal-title":"Science"},{"issue":"4","key":"4816_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317\u201334.","journal-title":"BioDrugs"},{"issue":"12","key":"4816_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","volume":"24","author":"R Shang","year":"2023","unstructured":"Shang R, Lee S, Senavirathne G, Lai EC. microRNAs in action: biogenesis, function and regulation. Nat Rev Genet. 2023;24(12):816\u201333.","journal-title":"Nat Rev Genet"},{"issue":"12","key":"4816_CR20","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/hmg\/ddg159","volume":"12","author":"O Corti","year":"2003","unstructured":"Corti O, Hampe C, Koutnikova H, Darios F, Jacquier S, Prigent A, Robinson JC, Pradier L, Ruberg M, Mirande M, et al. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet. 2003;12(12):1427\u201337.","journal-title":"Hum Mol Genet"},{"issue":"35","key":"4816_CR21","doi-asserted-by":"publisher","first-page":"7968","DOI":"10.1523\/JNEUROSCI.2172-05.2005","volume":"25","author":"HS Ko","year":"2005","unstructured":"Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KK, Pletnikova O, Troncoso J, Johnson B, Saffary R, Goh EL, et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38\/JTV-1, leads to catecholaminergic cell death. J Neurosci. 2005;25(35):7968\u201378.","journal-title":"J Neurosci"},{"issue":"10","key":"4816_CR22","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/nn.3500","volume":"16","author":"Y Lee","year":"2013","unstructured":"Lee Y, Karuppagounder SS, Shin JH, Lee YI, Ko HS, Swing D, Jiang H, Kang SU, Lee BD, Kang HC, et al. Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci. 2013;16(10):1392\u2013400.","journal-title":"Nat Neurosci"},{"issue":"3","key":"4816_CR23","doi-asserted-by":"publisher","first-page":"e1001351","DOI":"10.1371\/journal.pgen.1001351","volume":"7","author":"JW Choi","year":"2011","unstructured":"Choi JW, Kim DG, Lee AE, Kim HR, Lee JY, Kwon NH, Shin YK, Hwang SK, Chang SH, Cho MH, et al. Cancer-associated splicing variant of tumor suppressor AIMP2\/p38: pathological implication in tumorigenesis. PLoS Genet. 2011;7(3):e1001351.","journal-title":"PLoS Genet"},{"issue":"3","key":"4816_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/jmcb\/mjs018","volume":"4","author":"JW Choi","year":"2012","unstructured":"Choi JW, Lee JW, Kim JK, Jeon HK, Choi JJ, Kim DG, Kim BG, Nam DH, Kim HJ, Yun SH, et al. Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer. J Mol Cell Biol. 2012;4(3):164\u201373.","journal-title":"J Mol Cell Biol"},{"issue":"1","key":"4816_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12035-022-03073-1","volume":"60","author":"MG Kook","year":"2023","unstructured":"Kook MG, Byun MR, Lee SM, Lee MH, Lee DH, Lee HB, Lee EJ, Baek K, Kim S, Kang KS, et al. Anti-apoptotic splicing variant of AIMP2 recover mutant SOD1-induced neuronal cell death. Mol Neurobiol. 2023;60(1):145\u201359.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"4816_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0306-4522(01)00295-0","volume":"106","author":"E Petroske","year":"2001","unstructured":"Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP\/probenecid treatment. Neuroscience. 2001;106(3):589\u2013601.","journal-title":"Neuroscience"},{"issue":"10","key":"4816_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s003359900551","volume":"8","author":"DC Rogers","year":"1997","unstructured":"Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, Martin JE. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mammalian Genome. 1997;8(10):711\u20133.","journal-title":"Mammalian Genome"},{"issue":"10","key":"4816_CR28","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/mt.2008.171","volume":"16","author":"DM McCarty","year":"2008","unstructured":"McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther. 2008;16(10):1648\u201356.","journal-title":"Mol Ther"},{"issue":"8","key":"4816_CR29","first-page":"1086","volume":"123","author":"HR Xie","year":"2010","unstructured":"Xie HR, Hu LS, Li GY. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson\u2019s disease. Chin Med J. 2010;123(8):1086\u201392.","journal-title":"Chin Med J"},{"issue":"8","key":"4816_CR30","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1172\/JCI66778","volume":"123","author":"V Haurigot","year":"2013","unstructured":"Haurigot V, Marco S, Ribera A, Garcia M, Ruzo A, Villacampa P, Ayuso E, Anor S, Andaluz A, Pineda M, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest. 2013;123(8):3254\u201371.","journal-title":"J Clin Invest"},{"issue":"2","key":"4816_CR31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.virol.2008.11.037","volume":"385","author":"J O'Donnell","year":"2009","unstructured":"O\u2019Donnell J, Taylor KA, Chapman MS. Adeno-associated virus-2 and its primary cellular receptor\u2013Cryo-EM structure of a heparin complex. Virology. 2009;385(2):434\u201343.","journal-title":"Virology"},{"issue":"5","key":"4816_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.leukres.2005.09.001","volume":"30","author":"SH Ramkissoon","year":"2006","unstructured":"Ramkissoon SH, Mainwaring LA, Ogasawara Y, Keyvanfar K, McCoy JP Jr, Sloand EM, Kajigaya S, Young NS. Hematopoietic-specific microRNA expression in human cells. Leuk Res. 2006;30(5):643\u20137.","journal-title":"Leuk Res"},{"issue":"5654","key":"4816_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1126\/science.1091903","volume":"303","author":"CZ Chen","year":"2004","unstructured":"Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654):83\u20136.","journal-title":"Science"},{"issue":"3","key":"4816_CR34","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/jcb.21668","volume":"104","author":"R Liao","year":"2008","unstructured":"Liao R, Sun J, Zhang L, Lou G, Chen M, Zhou D, Chen Z, Zhang S. MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem. 2008;104(3):805\u201317.","journal-title":"J Cell Biochem"},{"key":"4816_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-biochem-060308-103103","volume":"79","author":"MR Fabian","year":"2010","unstructured":"Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351\u201379.","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"4816_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrg2936","volume":"12","author":"E Huntzinger","year":"2011","unstructured":"Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12(2):99\u2013110.","journal-title":"Nat Rev Genet"},{"issue":"7308","key":"4816_CR37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nature09267","volume":"466","author":"H Guo","year":"2010","unstructured":"Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835\u201340.","journal-title":"Nature"},{"issue":"3","key":"4816_CR38","doi-asserted-by":"publisher","first-page":"e0173550","DOI":"10.1371\/journal.pone.0173550","volume":"12","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Joyce BT, Kresovich JK, Zheng Y, Zhong J, Patel R, Zhang W, Liu L, Dou C, McCracken JP, et al. Blood pressure and expression of microRNAs in whole blood. PLoS ONE. 2017;12(3):e0173550.","journal-title":"PLoS ONE"},{"issue":"5","key":"4816_CR39","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1053\/j.gastro.2016.07.031","volume":"151","author":"M Rivkin","year":"2016","unstructured":"Rivkin M, Simerzin A, Zorde-Khvalevsky E, Chai C, Yuval JB, Rosenberg N, Harari-Steinfeld R, Schneider R, Amir G, Condiotti R, et al. Inflammation-induced expression and secretion of MicroRNA 122 leads to reduced blood levels of kidney-derived erythropoietin and anemia. Gastroenterology. 2016;151(5):999\u20131010.","journal-title":"Gastroenterology"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04816-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04816-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04816-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T06:04:22Z","timestamp":1705125862000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04816-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4816"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04816-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"27 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments complied with\u00a0the ARRIVE guidelines. The approved number of animal experiment is \u2018KHUASP(SE)-18-101\u2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}],"article-number":"53"}}